APR 03, 2018 08:27 PM PDT

Two-Drug Strategy for Non-Small Cell Lung Cancer (NSCLC)

WRITTEN BY: Nouran Amin

According to the National Cancer Institute, lung cancer is the most common cause of cancer death for both men and women in the U.S. More specifically, non-small cell lung cancer (NSCLC) encompasses 85% of all lung cancers.

Investigators seeking new treatment options for patients of lung cancer have found a combination of drugs that are effective for NSCLC specifically. These drugs target epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF), the targeting works to effectively inhibit the cancer from using TNF as way to escape and allowing the cancer to be sensitive to the EGFR treatment.

"There has been a tremendous effort over the past several years to block EGFR as a treatment for lung cancer, but this therapy only works in a small subset of patients. The cancer fights back with a bypass pathway," explains lead researcher Dr. Amyn Habib with the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern as well as a staff physician at the Dallas Veterans Affairs Medical Center. "Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients.” These research findings stem from the same combination of drug treatments that were found to be successful in a glioblastoma mouse model.Bottom Rows: Tumors treated w/ two-drug strategy. Top Rows: Tumors left untreated or w/ a single treatment. Credit: UT Southwestern via Science Daily

Furthermore, these anti-EGFR/TNF two-strategy drugs were found to be well tolerated and with few side effects which was because they worked to target specific molecules within cancer cells. Thus, anti-EGFR/TNF drugs are more advantageous than traditional chemotherapeutic treatments which have unpleasant side-effects on a patient.

Investigators will continue their research for a phase 2 clinical trial of using the two-drug strategy; which has already been approved by the FDA. The prospective clinical studies are being planned to test the two-drug treatment in lung cancer patients as well as glioblastomas. "If this strategy is effective, then it might be broadly applicable not only against lung cancer but also against other cancers that express EGFR, which include brain, colon, and head and neck cancers," says lead clinical studies leader Dr. Gerber, an Associate Professor of Internal Medicine and Clinical Sciences.

Until recently, EGFR inhibitors were studied to be effective at treating a small percentage of non-small cell lung cancers that have a variant form of EGFR. However, with two-drug strategy, treatment could be effective for all forms of non-small cell lung cancers.

The research was published in the Journal of Clinical Investigation.

Source: Journal of Clinical Investigation, Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Immunotherapeutic Targets A Blood-Clotting Protein
Fibrin is a blood protein that normally does not cross to the brain, however, several neurological disorders have a defect in the blood-brain barrier that ...
NOV 30, 2018
Immunology
NOV 30, 2018
Aspirin May Impove MS Symptoms
The medical benefits of aspirin have been known since ancient times. Hippocrates, c. 400 BC, prescribed the salicylate-rich bark and leaves of the willow t...
DEC 06, 2018
Drug Discovery
DEC 06, 2018
Repurposing Cancer Drugs For HPV Treatment
Drug repurposing is transforming the health care world. The idea that old, previously-- FDA approved drugs could be altered and to be used again for the tr...
DEC 06, 2018
Cannabis Sciences
DEC 06, 2018
Targeting CB1 Receptors With Antibodies
A recent press release from the pharmaceutical company Integral Molecular, written by Kate Kadash-Edmondson, has demonstrated the safety of a new ther...
DEC 17, 2018
Health & Medicine
DEC 17, 2018
Microglial Priming And Pain
Microglia are in primed states when injury happens and acute exposure to opioids activates them further creating pain sensitivity....
FEB 11, 2019
Chemistry & Physics
FEB 11, 2019
Actinium-based Targeted Alpha Therapy Delivers A Combo Punch
Radiotherapy is a staple among many medical interventions to treat cancer. Besides external beam radiotherapy and sealed radio-source therapy, it is common...
Loading Comments...